Once infected by SARS-CoV-2, would you like to know your health status evolution? This is Biosfer Teslab commitment in the SARS-CoV-2 pandemic. The Spanish Institute of Health Research Pere Virgili, Fundación Alcorcón University Hospital, SCIENCE&STRATEGY SL, Laboratorios Rubió SA, and Biosfer Teslab together with Treat systems (Denmark), Kinesys Consulting (UK), EuroCrime (Italy) have built… Read More »Predicting the future of health
The sixth edition of the Alberto Elzaburu Foundation Innovation Award recognizes Núria Amigó, CEO of Biosfer Teslab, as a young entrepreneur The Alberto Elzaburu Foundation, for the sixth consecutive year, granted yesterday November 5 at the Mapfre Auditorium in Madrid, its Innovation Award, which recognizes the efforts of young Spanish entrepreneurs and researchers and values… Read More »Alberto Elzaburu Foundation award
The student Rocío Fuertes has obtained a doctoral degree from the University Rovira i Virgili after defending her thesis “1H-NMR glycoprotein analysis: An Advanced approach for Inflammatory diseases diagnosis”, for which she has achieved the status of ‘cum laude’ by unanimity of the court. Developed between Biosfer Teslab -within the framework of the Industrial Doctorate… Read More »Biosfer Teslab presents its first industrial doctoral thesis
Last December, Núria Amigó took part in the round table on “Disruptive innovations and start-ups”. You can see her speech here (video in Catalan)
Dr. Adriana Saltijeral of the University Hospital del Tajo (Aranjuez, Madrid) interviews Dr. Leopoldo Pérez de Isla, of the San Carlos Clinical Hospital of Madrid and member of the Scientific Committee of the Family Hypercholesterolemia Foundation, to talk about the importance of knowing the size of LDL cholesterol particles to stratify cardiovascular risk. Dr. Pérez… Read More »LDL cholesterol: the poison is stored in small bottles
Standard values of number and size of lipoprotein particles per age and gender, using Nuclear Magnetic Resonance
The XXIX Convention of the Spanish Atherosclerosis Society (SEA) took place in Granada last May, and its scientific committee chose another of the I+D projects developed in Biosfer Teslab to be presented as an oral communication. The Communication title is “Standard values of number and size of lipoprotein particles per age and gender, using Nuclear… Read More »Standard values of number and size of lipoprotein particles per age and gender, using Nuclear Magnetic Resonance
In May, the XXIX Convention of the Spanish Atherosclerosis Society (SEA) took place in Granada, and its scientific committee chose one of the I+D projects developed in Biosfer Teslab to be presented as an oral communication. The presented Communication, whose title is “MEtabolomics characterization for patients with Rheumatoid Arthritis (RA) using 1H-Nuclear magnetic resonance (1H… Read More »Metabolomics characterization for patients with Rheumatoid Arthritis using spectroscopy
Biosfer Teslab took part in the XXIX National Convention of the Spanish Atherosclerosis Society (SEA), held this past May. Specifically, the Liposcale test was the main topic of the Round Table with the presence of Fernández Pardo, Luis Masana Marín, Domingo Orozco and Núria Amigó Grau. More information here.
On the 21th of May, Biosfer Teslab took part in the 8th Cardiovascular Meeting of SEMERGEN, in Santander. Nuria Amigó took part in a session which name was “The significance of the size of lipoproteins in cardiovascular risk filtering. More information here.
The Di@bet.es 2 study will define risk scales that will let us apply prevention programs for less people, but better targeted
The Research Program of CIBERDEM is focused on the study of the epidemiology of diabetes mellitus; genetics, epigenetics and related environmental factors with this pathology, and the associated molecular mechanisms to the onset and progress of the cronical complications of the diabetes. In addition, in the framework of this program, there are other nutritional issues… Read More »The Di@bet.es 2 study will define risk scales that will let us apply prevention programs for less people, but better targeted